Press release
Triple Negative Breast Cancer Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
Upcoming therapies, such as TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics), and others, have the potential to create a significant positive shift in the TNBC market size and the treatment scenario.
"Triple Negative Breast Cancer Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Triple Negative Breast Cancer Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Triple Negative Breast Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Triple Negative Breast Cancer Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Triple Negative Breast Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Triple Negative Breast Cancer Therapeutics Domain:
https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Triple Negative Breast Cancer Therapeutics Analysis
Currently, the treatment paradigm for TNBC includes a few treatment options, such as systemic chemotherapies, neoadjuvant or adjuvant chemotherapy, surgery, and radiation. The Triple Negative Breast Cancer market holds few US FDA-approved drugs, such as KEYTRUDA (pembrolizumab) by Merck Sharpe and Dohme, LYNPARZA (olaparib) by AstraZeneca, TRODELVY (sacituzumab govitecan) by Gilead Sciences, etc. However, various off-label drugs are used for treating TNBC, which include Paclitaxel (Abraxane), Erbulin (Halaven), Carboplatin, Cisplatin, Docetaxel, etc. To further improve the treatment scenario, several major pharma and biotech giants are actively working in the Triple Negative Breast Cancer Therapeutics market.
The Leading Players in the Triple Negative Breast Cancer Therapeutics Market Include:
• Astellas
• AstraZeneca
• Clovis Oncology
• CytoDyn
• Gilead Science
• HiberCell
• Hoffmann-La Roche
• Immunomedics
• Imprime PGG
• Infinity Pharmaceuticals
• Merck
• Roche
• Tesaro
And Many Others
Triple Negative Breast Cancer Emerging and Marketed Therapies Covered in the Report Include:
• Atezolizumab: Roche
• Capitasertib: AstraZeneca
• Cobimetinib: Roche
• Enzalutamide: Pfizer/Astellas
• HiberCell: Imprime PGG
• Ipatasertib: Roche
• IPI-549 (Eganelisib): Infinity Pharmaceuticals
• KEYTRUDA (pembrolizumab): Merck & Co
• Niraparib: Tesaro
• Pembrolizumab: Merck
• Rucaparib: Clovis Oncology
• Sacituzumab Govitecan: Immunomedics
• TRODELVY (sacituzumab govitecan-hziy): Gilead Sciences
• HiberCell: Imprime PGG
• MDNA11: Medicenna Therapeutics
• Leronlimab (PRO 140): CytoDyn
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Triple Negative Breast Cancer Current Treatment Patterns
4. Triple Negative Breast Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Triple Negative Breast Cancer Late-Stage Products (Phase-III)
7. Triple Negative Breast Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Triple Negative Breast Cancer Discontinued Products
13. Triple Negative Breast Cancer Product Profiles
14. Triple Negative Breast Cancer Key Companies
15. Triple Negative Breast Cancer Key Products
16. Dormant and Discontinued Products
17. Triple Negative Breast Cancer Unmet Needs
18. Triple Negative Breast Cancer Future Perspectives
19. Triple Negative Breast Cancer Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Triple Negative Breast Cancer Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies here
News-ID: 2977695 • Views: …
More Releases from DelveInsight Business Research LLP
The Parkinson's Disease Market Size in the 7MM was ~USD 3,539 Million in 2025, a …
DelveInsight's "Parkinson Disease Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Parkinson Disease, historical and forecasted epidemiology as well as Parkinson Disease therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore Parkinson Disease Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from Parkinson Disease Market Report
• On…
Chronic Obstructive Pulmonary Disease Market Size in the 7MM is projected to gro …
DelveInsight's "Chronic Obstructive Pulmonary Disease Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Chronic Obstructive Pulmonary Disease, historical and forecasted epidemiology as well as Chronic Obstructive Pulmonary Disease therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore Chronic Obstructive Pulmonary Disease Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @…
Atypical Hemolytic Uremic Syndrome Market Size in the 7MM was USD 1,300 million …
DelveInsight's "Atypical Hemolytic Uremic Syndrome Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Atypical Hemolytic Uremic Syndrome, historical and forecasted epidemiology as well as Atypical Hemolytic Uremic Syndrome therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore Atypical Hemolytic Uremic Syndrome Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @…
Osteogenesis Imperfecta Market Size in the 7MM was ~USD 30 million in 2023 and i …
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast 2034" report delivers an in-depth understanding of Osteogenesis Imperfecta, historical and forecasted epidemiology as well as Osteogenesis Imperfecta therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore Osteogenesis Imperfecta Market Trends, treatment landscapes, and emerging therapies shaping the future. Download sample report @ https://www.delveinsight.com/sample-request/osteogenesis-imperfecta-oi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from Osteogenesis Imperfecta Market Report
• On…
More Releases for Triple
SmoothSpine Triple Fusion Massager Reviews Does the Smoothspine Triple Fusion Ma …
If you have ever experienced the sharp, electric jolt of sciatica traveling down your leg, or the dull, aching throb in your lower back after a long drive, you understand that back pain is not just a physical nuisance. It is an emotional drain. It steals your focus, ruins your sleep, and eventually, it starts to dictate your life. For years, I found myself trapped in the expensive cycle of…
HuxQ10 Relaunches with New Triple Approval
Huxley Europe is celebrating the relaunch of its HuxQ10 capsules, and is delighted to announce that they are approved Halal by Halal Trust, approved Kosher and certified vegan. Three reasons to celebrate!
Coenzyme Q10, also known as Ubiquinone or simply Q10, is a vitamin like substance that occurs naturally in the body. The first recognised role of CoQ10 was in mitochondrial biogenetics, where it plays a central role in…
Triple Net Lease Properties And Tenants
Aug 26, 2019 - A triple net or NNN lease is a single-tenant arrangement that requires the tenant to pay all operating expenses associated with the property they've rented. NNN investors enjoy a regular flow of income without any liabilities as all additional expenses are covered by the tenant. This kind of investment is suitable for investors who don't want to spend time and money in the maintenance of their…
TRIPLE TRIPADVISOR SUCCESS FOR ANOKI RESTAURANT
Anoki has reinforced its reputation as one of the UK’s leading fine dining restaurants after all three restaurants were inducted into TripAdvisor’s coveted Hall of Fame.
The restaurants in Derby, Nottingham and Burton have received the accolade after being awarded the prestigious Certificate of Excellence for five consecutive years.
Now in its ninth year, The TripAdvisor Certificate of Excellence celebrates hospitality businesses that are consistently excellent – having earned great traveller reviews…
Triple award winning awning model
Cassette awning markilux 970 now also awarded iF Design Award
In autumn, last year, awning expert markilux already enjoyed the success of its new cassette awning, the markilux 970. Already in the first year it managed to receive two design awards. At the beginning of 2014 a third award followed: the internationally renowned iF Design Award. More than 5,000 registrations from 59 countries participated in the competition in 2016.
According to…
Triple Diamond Energy Corp. Begins Triple Diamond Energy No. 2 Joint Venture
Triple Diamond Energy Corp., a Texas-based independent oil and gas drilling company, is currently preparing to drill the No. 2 Joint Venture oil project.
ADDISON, TX -- Texas-based oil and gas exploration and production company, Triple Diamond Energy Corp., has announced that it is now in the planning stages of the Triple Diamond Energy No. 2 Joint Venture oil well project. The project consists of plans to drill four development wells.…
